Compare BridgeBio Pharma Inc (BBIO) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Fidelity National Information Servcs Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Fidelity National Information Servcs Inc trades at $40.58 (market cap $20.97B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | FIS | |
|---|---|---|
Market Cap | $16.46B | $20.97B |
Sector | Health | Technology |
52-Week High | $90.17 | $81.94 |
52-Week Low | $44.81 | $37.72 |
Enterprise Value | $18.02B | $41.37B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
FIS trades at $41.93, down 0.12% on the day, with a bullish technical signal from moving averages and strong institutional support. The stock shows attractive valuation metrics with a P/E of 8.13 and P/S of 1.91, while recent earnings have generally beaten expectations. Positive news flow highlights FIS's leadership in AI-driven banking technology and cloud infrastructure, with upcoming Q2 2026 earnings on August 4, 2026, providing a near-term catalyst.
The outlook for FIS is positive given its low valuation, analyst consensus price target of $52.57 (25% upside), and strategic focus on digital banking growth. Key risks include execution challenges post-Worldpay divestiture and rising debt levels, but strong cash flow generation and dividend yield of approximately 1.05% support shareholder returns. Institutional sentiment remains bullish with 58% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
